30 Years of Evidence
Join the experts’ corner
Featured Content
SBRT Focal Boost for Localised Prostate Cancer: Primary Outcomes of the SPARC Prospective Trial
Efficacy and Toxicity of Moderately Hypofractionated Radiotherapy via Helical TomoTherapy versus Conventional Radiotherapy Combined with Concurrent Chemotherapy for Patients with Unresectable
Stage III NSCLC
Feasibility of SBRT with CyberKnife in the Scenario of Lung Metastases Re-RT: Monoinstitutional Experience
Stereotactic Body Radiotherapy for Recurrent or Oligometastatic Uterine Cervix Cancer: A Cooperative Study of the Korean Radiation Oncology Group (KROG 14-11)
Park HJ, Chang AR, Seo Y, Cho CK, Jang WI, Kim MS, Choi C | Anticancer Res | 2015
Stereotactic Radiotherapy in the Retreatment of Recurrent Cervical Cancers, Assessment of Toxicity, and Treatment Response: Initial Results and Literature Review
Pontoriero A, Iatì G, Aiello D, Pergolizzi S | Technol Cancer Res Treat | 2016
Long-term results of robotic radiosurgery for non brachytherapy patients with cervical cancer
Morgenthaler J, Köhler C, Budach V, Sehouli J, Stromberger C, Besserer A, Trommer M, Baues C, Marnitz S | Strahlenther Onkol | 2021
CyberKnife Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Gynecological Cancers
Kataria T, Naga P, Banerjee S, Gupta D, Narang K, Tayal M, Bisht SS | South Asian J Cancer | 2021
CyberKnife® SBRT for Prostate Cancer: Is 5 better than 44?
Olusola Obayomi-Davies
Building a Prostate SBRT Program with the CyberKnife® System
Jonathan A. Haas
Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints
Meier RM, Bloch DA, Cotrutz C, Beckman AC, Henning GT, Woodhouse SA, Williamson SK, Mohideen N, Dombrowski JJ, Hong RL, Brachman DG, Linson PW, Kaplan ID. | Int J Radiat Oncol Biol Phys | 2018
Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial
Wang K, Chen RC, Kane B, Medbery CA, Underhill K, Gray JR, Peddada AV, Fuller DB | Int J Radiat Oncol Biol Phys | 2018
5-year Biochemical Outcomes of Stereotactic Body Radiotherapy with Intraprostatic Dose Escalation for Unfavorable Prostate Cancer
Blacksburg SR, Aghdam N, Royce TJ, Burri RJ, Obayomi-Davies O, Mezeckis M, Meier R, Fuller DB, Chen RC, Lanciano RM, Haas JA, Collins SP | Int J Radiat Oncol Biol Phys | 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van As N; PACE Trial Investigators | Lancet Oncol | 2019
Prostate SBRT: Comparison the Efficacy and Toxicity of Two Different Dose Fractionation Schedules
Fuller DB, Naitoh J, Shirazi R, Crabtree T, Mardirossian G | Front Oncol | 2020
Favorable Biochemical Freedom From Recurrence With Stereotactic Body Radiation Therapy for Intermediate and High-Risk Prostate Cancer: A Single Institutional Experience With Long-Term Follow-Up
Ricco A, Barbera G, Lanciano R, Feng J, Hanlon A, Lozano A, Good M, Arrigo S, Lamond J, Yang J | Front Oncol | 2020
Effectiveness and Safety of Tissue Expander for Adjuvant Helical Tomotherapy in Curatively Resected Retroperitoneal Sarcoma
Yu JI, Lim DH, Park HC, Jung SH, Jeon SJ, Nam H, Kim B, Kim SJ, Park JB | Anticancer Res | 2018
Neoadjuvant image-guided helical intensity modulated radiotherapy of extremity sarcomas – a single center experience
Peeken JC, Knie C, Kessel KA, Habermehl D, Kampfer S, Dapper H, Devecka M, von Eisenhart-Rothe R, Specht K, Weichert W, Wörtler K, Knebel C, Wilkens JJ, Combs SE | Radiat Oncol | 2019
Prospective evaluation of multitarget treatment of pediatric patients with helical intensity-modulated radiotherapy
Salfelder MA, Kessel KA, Thiel U, Burdach S, Kampfer S, Combs SE | Strahlenther Onkol | 2020
Efficacy and toxicity of chemoradiation in patients with anal cancer–a retrospective analysis
Koerber SA, Slynko A, Haefner MF, Krug D, Schoneweg C, Kessel K, Kopp-Schneider A, Herfarth K, Debus J, Sterzing F | Radiat Oncol | 2014
Patient reported quality of life after helical IMRT based concurrent chemoradiation of locally advanced anal cancer
Joseph K, Vos LJ, Warkentin H, Paulson K, Polkosnik LA, Usmani N, Tankel K, Severin D, Nijjar T, Schiller D, Wong C, Ghosh S, Mulder K, Field C | Radiother Oncol | 2016
Modern intensity-modulated radiotherapy with image guidance allows low toxicity rates and good local control in chemoradiotherapy for anal cancer patients
De Bari B, Lestrade L, Franzetti-Pellanda A, Jumeau R, Biggiogero M, Kountouri M, Matzinger O, Miralbell R, Bourhis J, Ozsahin M, Zilli T | J Cancer Res Clin Oncol | 2018
Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy
Klausner G, Blais E, Jumeau R, Biau J, de Meric de Bellefon M, Ozsahin M, Zilli T, Miralbell R, Thariat J, Troussier I | Med Oncol | 2018
TomoTherapy® for Advanced Rectal Cancer
Xiaoliang Liu